focus -WSS

focus

author：focus 2025-10-01 23:08:03 - browse：72379

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： FDA poised to publish guidelines for clinical trial diversity

WSS

Study finds gene variants tied to breast cancer risk in Black women

RaDonda Vaught to speak at CommonSpirit event on patient safety

Obesity now affects over 1 billion people worldwide, study finds

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Fentanyl is making it harder to start addiction treatment

Bird flu surveillance in wastewater gets boost from consortium

Wikipedia

focus

hotspot

Peter Hotez and the public health issue of online harassment

Biotech companies concerned about China biosecurity crackdown

The high cost of giving birth even with insurance

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Alkermes shareholders re

Flu vaccine offering decent levels of protection this winter, new data show

Affirmative action in medical school literally saved lives

Liver decline slowed by off

Affirmative action in medical school literally saved lives

Bird flu surveillance in wastewater gets boost from consortium

focus

Eyeing GLP

House looks to weaken Medicare negotiation

Liver decline slowed by off

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Medical device lobby: We're tired of waiting on Medicare coverage

As a primary care physician, here's how I hope to partner with AI

leisure time

hotspot

Wikipedia

explore